Subscribe
Be the first with the news that moves the market- Xebra Brands (CSE:XBRA) signs first cultivation agreement in Mexico with Chapingo University
- The agreement will focus on the first commercial cultivation of cannabis and hemp with less than 1 per cent THC
- The agreement between the company and Chapingo University is the first of its kind
- It will also enable cultivation, research and development protocols for legal cannabis cultivation in Mexico
- Shares of Xebra Brands (XBRA) are unchanged at C$0.07
Xebra Brands (XBRA) has signed its first cultivation agreement in Mexico with Chapingo University.
The company said the agreement will focus on the first cultivation of cannabis and hemp with less than 1 per cent THC in Mexico in addition to the research and development of cannabis cultivators in Mexico.
Collaborative efforts between the company and the university will include:
- Importing a wide selection of cannabis seeds
- Cultivating and analyzing the behaviour and productivity of industrial hemp flower and fibre under greenhouse conditions
- Evaluating the strains for different regions across Mexico
- Producing high cannabinoid-yielding sativa L cannabis crops with less than 1 per cent THC in field and greenhouse environments
“It is an unbeatable opportunity, we couldn’t be more excited to expand our relationship with Chapingo University and expand our partnership with this commercial agreement to legally cultivate for the first time in Mexico with the best agricultural experts in the country,” Rodrigo Gallardo Valencia, director of Xebra Brands, said in a statement.
Based out of Vancouver, B.C., Xebra Brands is a cannabis cultivation and product company with global brands and intellectual property.
The company’s focus is on beverages, wellness and leisure, and it was granted the first authorization for a company by COFEPRIS in Mexico.
Shares of Xebra Brands (XBRA) are unchanged at C$0.07.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
